{"id":5347,"date":"2024-11-06T12:00:00","date_gmt":"2024-11-06T09:00:00","guid":{"rendered":"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/2026\/01\/19\/sut-degisikligi-hk\/"},"modified":"2026-01-19T11:12:07","modified_gmt":"2026-01-19T08:12:07","slug":"sut-degisikligi-hk","status":"publish","type":"post","link":"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/2024\/11\/06\/sut-degisikligi-hk\/","title":{"rendered":"SUT DE\u011e\u0130\u015e\u0130KL\u0130\u011e\u0130 HK."},"content":{"rendered":"
\n

02.11.2024 Tarihli SUT De\u011fi\u015fikli\u011fi Hakk\u0131nda Bilgi Notu
\n <\/o:p><\/b><\/p>\n

 <\/b><\/p>\n

A\u015fa\u011f\u0131da yer alan d\u00fczenlemeler, 09 Kas\u0131m 2024 tarihinde y\u00fcr\u00fcrl\u00fc\u011fe girecektir.<\/o:p><\/p>\n

\n
\n  
\n <\/o:p>v  <\/span><\/span>SUT\u2019un 2.4.3-B maddesinde yap\u0131lan de\u011fi\u015fiklik ile, g<\/span>rip a\u015f\u0131s\u0131 bedelinin her Eyl\u00fcl ila Mart d\u00f6nemleri i\u00e7erisinde re\u00e7ete edildi\u011finde bir defaya mahsus olmak \u00fczere kar\u015f\u0131lanaca\u011f\u0131 d\u00fczenlendi.<\/span><\/p>\n

 <\/b>v  <\/span><\/span>SUT\u2019un <\/span>4.2.1 maddesine bimekizumab (B\u0131mzelx 160 Mg\/Ml SC Enjeksiyonluk \u00c7\u00f6zelti \u0130\u00e7eren Kullan\u0131ma Haz\u0131r Kalem) etkin maddesi eklenerek, geri \u00f6denme ko\u015fullar\u0131 <\/span>belirlendi.<\/span><\/p>\n

\n
\n  
\n <\/o:p>v  <\/span><\/span>Biyolojik ajanlar i\u00e7in ara verme kriterleri belirlendi. Bu s\u00fcre; Rituksimab (Mabthera flakon) i\u00e7in 12 ay, di\u011fer biyolojik ajanlar i\u00e7in 6 ay olarak belirlendi.<\/span><\/p>\n

\n
\n  
\n <\/o:p>v  <\/span><\/span>Biyolojik ajanlarda, <\/span>etkisizlik veya yan etki nedeniyle ila\u00e7 de\u011fi\u015fimi durumunda tedaviye ba\u015flang\u0131\u00e7 dozu ile devam edilece\u011fi konusu netle\u015ftirildi.<\/span><\/p>\n

\n
\n  
\n <\/o:p>v  <\/span><\/span>Ayn\u0131 hasta i\u00e7in iki farkl\u0131 tan\u0131 ile iki farkl\u0131 anti-TNF veya biyolojik ajan\u0131n birlikte kullan\u0131lmas\u0131 halinde bedellerinin Kurumca kar\u015f\u0131lanmayaca\u011f\u0131 <\/span>d\u00fczenlendi.<\/span><\/p>\n

\n
\n  
\n <\/o:p>v  <\/span><\/span>Biyolojik ajan tedavi basamaklar\u0131nda de\u011fi\u015fiklik yap\u0131lmas\u0131 halinde, tedavinin ba\u015fland\u0131\u011f\u0131 tarihteki Sa\u011fl\u0131k Uygulama Tebli\u011finde yer alan ba\u015flang\u0131\u00e7 kriterleri ge\u00e7erli olup, bu konudaki teredd\u00fctler giderildi.<\/span><\/p>\n

\n
\n  
\n <\/o:p>v  <\/span><\/span>\u00dclseratif Kolit hastal\u0131\u011f\u0131nda ba\u015flang\u0131\u00e7 rapor s\u00fcreleri 4 ay, idame rapor s\u00fcreleri 6 ay olarak d\u00fczenlendi.<\/span><\/p>\n

\n
\n  
\n <\/o:p>v  <\/span><\/span>Tofacitinib (Xeljanz Film Tablet, Jandark Film Kapl\u0131 Tablet) etkin maddesinin Poliartik\u00fcler Juvenil \u0130diyopatik Artriti (PJ\u0130A) tan\u0131s\u0131nda geri \u00f6denme ko\u015fullar\u0131 belirlendi.<\/span><\/p>\n

\n
\n  
\n <\/o:p>v  <\/span><\/span>Kanakinumab (Ilar\u0131s Enjeksiyonluk \u00c7\u00f6zelti \u0130\u00e7in Toz \u0130\u00e7eren Flakon) etkin maddesinin (T\u00fcm\u00f6r nekroz edici fakt\u00f6r resept\u00f6r\u00fc 1 ile ili\u015fkili periyodik ate\u015f sendromlar\u0131) TRAPS, (Hiper\u0130mm\u00fcnglob\u00fclin D Sendromu) HIDS ve (Mevalonat Kinaz eksikli\u011fi) MKD tan\u0131lar\u0131nda geri \u00f6denme ko\u015fullar\u0131 belirlendi.<\/span><\/p>\n

\n
\n  
\n <\/o:p>v  <\/span><\/span>Lamotrijin (Lam\u0131ctal DC \u00c7\u00f6z\u00fcn\u00fcr\/\u00c7i\u011fneme Tableti) etkin maddesinin, bipolar bozukluk endikasyonunda psikiyatri uzman hekimleri taraf\u0131ndan veya bu hekimlerce d\u00fczenlenen uzman hekim raporuna dayan\u0131larak t\u00fcm hekimlerce re\u00e7ete edilebilece\u011fi d\u00fczenlendi.<\/span><\/p>\n

\n
\n  
\n <\/o:p>v  <\/span><\/span>D\u00fc\u015f\u00fck molek\u00fcl a\u011f\u0131rl\u0131kl\u0131 heparinlerde (DMAH) 1 y\u0131ldan uzun s\u00fcreli kullan\u0131mda; onkoloji, hematoloji, kalp damar cerrahisi, kardiyoloji, g\u00f6\u011f\u00fcs hastal\u0131klar\u0131 veya n\u00f6roloji uzman hekimlerinden herhangi birinin bulundu\u011fu sa\u011fl\u0131k kurulu raporuna istinaden t\u00fcm hekimlerce re\u00e7ete edilmesi halinde bedellerinin Kurumca kar\u015f\u0131lanaca\u011f\u0131 d\u00fczenlendi.<\/span><\/p>\n

\n
\n  
\n <\/o:p>v  <\/span><\/span>Spesifik olmayan imm\u00fcnglobulinlerin geri \u00f6denme ko\u015fullar\u0131, IV veya IV \/ SC ile uygulama yolu sadece SC olarak ikiye ayr\u0131ld\u0131. Primer immun yetmezli\u011fi tan\u0131s\u0131nda yaln\u0131zca sa\u011fl\u0131k kurulu raporu ile geri \u00f6deme kapsam\u0131 d\u00fczenlendi.<\/span><\/p>\n

\n
\n  
\n <\/o:p>v  <\/span><\/span>Akut Hepatit B tedavisinde antivirallerin \u00f6denme ko\u015fullar\u0131 belirlendi. Kronik Hepatit B tedavisine ili\u015fkin biyopsi ve benzeri kriterlerde de\u011fi\u015fiklik yap\u0131ld\u0131.<\/span><\/p>\n

\n
\n  
\n <\/o:p>v  <\/span><\/span>Koloni Uyar\u0131c\u0131 Fakt\u00f6rler olan <\/span>filgrastim (Neupogen Roche Haz\u0131r \u015e\u0131r\u0131nga), lenograstim <\/span>(Granocyte Enjeksiyonluk\/Inf\u00fczyonluk Liyofilize Toz \u0130\u00e7eren Flakon), <\/span>pegfilgrastim (Neulast\u0131m S.C. Enjeksiyon \u0130\u00e7in Kullan\u0131ma Haz\u0131r \u015e\u0131r\u0131nga) ve lipegfilgrastim (Lonquex Kullan\u0131ma Haz\u0131r Dolu Enjektor) etkin maddeleri i\u00e7in, re\u00e7ete ve rapor d\u00fczenleyebilecek bran\u015flar d\u00fczenlendi.<\/span><\/p>\n

\n
\n  
\n <\/o:p>v  <\/span><\/span>\u00d6zel d\u00fczenleme yap\u0131lan ve kanser tedavisinde kullan\u0131lan baz\u0131 etkin maddelerin geri \u00f6denme ko\u015fullar\u0131na d\u00fczenlemeler ve eklemeler yap\u0131ld\u0131.<\/span><\/p>\n

\n
\n  
\n <\/o:p>v  <\/span><\/span>Ranolazin (Lat\u0131xa Uzat\u0131lm\u0131\u015f Sal\u0131ml\u0131 Tablet) etkin maddesi i\u00e7in d\u00fczenlenecek rapor s\u00fcresi 2 y\u0131la \u00e7\u0131kar\u0131ld\u0131.<\/span><\/p>\n

\n
\n  
\n <\/o:p>v  <\/span><\/span>T\u0131bbi mamalar\u0131n, kronik b\u00f6brek hastal\u0131\u011f\u0131 (evre 2-5) tan\u0131s\u0131 olan 3 ya\u015f ve \u00fczeri \u00e7ocuklarda geri \u00f6denme ko\u015fullar\u0131 belirlendi.<\/span><\/p>\n

\n
\n  
\n <\/o:p>v  <\/span><\/span>Pregabalin (Lyr\u0131ca Kaps\u00fcl) ve gabapentin (Gabaset Kapsul) etkin maddeleri i\u00e7in, ikinci ve \u00fc\u00e7\u00fcnc\u00fc basamak sa\u011fl\u0131k hizmeti sunucular\u0131nda rapor d\u00fczenlenmesi sa\u011fland\u0131. Ayr\u0131ca pregabalin (Lyr\u0131ca Kaps\u00fcl) etkin maddesinin kronik kas iskelet a\u011fr\u0131s\u0131 ile fibromiyaljide ikinci ve \u00fc\u00e7\u00fcnc\u00fc basamak sa\u011fl\u0131k kurumlar\u0131nda rapor d\u00fczenlenmesi sa\u011flanarak, bran\u015flar aras\u0131na n\u00f6roloji eklendi.<\/span><\/p>\n

\n
\n  
\n <\/o:p>v  <\/span><\/span>Fakt\u00f6r kullan\u0131m\u0131 i\u00e7in, ilk raporun \u00fc\u00e7\u00fcnc\u00fc basamak resmi sa\u011fl\u0131k hizmeti sunucular\u0131nda d\u00fczenlenme zorunlulu\u011fu getirildi.<\/span><\/p>\n

\n
\n  
\n <\/o:p>v  <\/span><\/span>Kontrast maddelerin geri \u00f6denme ko\u015fullar\u0131 d\u00fczenlendi ve kontrast maddenin t\u00fcr\u00fcne g\u00f6re kar\u015f\u0131lanabilecek kutu say\u0131lar\u0131 belirlendi.<\/span><\/p>\n

\n
\n  
\n <\/o:p>v  <\/span><\/span>Ranibizumab (Lucentis) etkin maddesinin premat\u00fcre retinopatisi tedavisinde geri \u00f6denme ko\u015fullar\u0131 belirlendi.<\/span><\/p>\n

\n
\n  
\n <\/o:p>v  <\/span><\/span>Anti-VEGF ila\u00e7larda ila\u00e7 de\u011fi\u015fimi gereken idame tedavilerde, y\u00fckleme dozu aranmas\u0131 zorunlulu\u011fu kald\u0131r\u0131ld\u0131.<\/span><\/p>\n

\n
\n  
\n <\/o:p>v  <\/span><\/span>Parenteral demir preparatlar\u0131nda geri \u00f6deme ko\u015fullar\u0131na demir eksikli\u011fi tedavisine ili\u015fkin ibare eklendi.<\/span><\/p>\n

\n
\n  
\n <\/o:p>v  <\/span><\/span>Gonadotropin kullan\u0131m ilkelerinde, k<\/span>ombine FSH-LH preparatlar\u0131 ile koryogonadotropin alfa etkin maddeli ila\u00e7lar\u0131n kombine kullan\u0131m\u0131n\u0131n engellenmesine y\u00f6nelik d\u00fczenleme yap\u0131ld\u0131. \u00d6rnek olarak, Menagon ve Ovitrelle birlikte kar\u015f\u0131lanmaz.<\/span><\/p>\n

\n
\n  
\n <\/o:p>v  <\/span><\/span>Daratumumab (Darzalex) etkin maddesinin Amiloidoz hastal\u0131\u011f\u0131nda geri \u00f6denme ko\u015fullar\u0131 belirlendi.<\/span><\/p>\n

\n
\n  
\n <\/o:p>v  <\/span><\/span>Dupilumab (Dupixent) etkin maddesi i\u00e7in endikasyon uyumu zorunlulu\u011fu getirildi.<\/span><\/p>\n

\n
\n  
\n <\/o:p>v  <\/span><\/span>Sefaklor (Cec Efervesan Tablet) etkin maddesinin efervesan formlar\u0131n\u0131n enfeksiyon hastal\u0131klar\u0131 uzman\u0131 taraf\u0131ndan re\u00e7ete edilebilece\u011fi d\u00fczenlendi.<\/span><\/p>\n

\n
\n  
\n <\/o:p>v  <\/span><\/span>\u0130vermektin (Ziver) etkin maddesinin, K\u0131sa \u00dcr\u00fcn Bilgisinde (K\u00dcB) yer alan pozolojisini a\u015fmayacak dozda re\u00e7etelenece\u011fi d\u00fczenlendi.<\/span><\/p>\n

\n
\n  
\n <\/o:p>v  <\/span><\/span>C1-esteraz inhibit\u00f6rleri i\u00e7in geri \u00f6denme ko\u015fullar\u0131 d\u00fczenlendi. (C\u0131nryze Iv Enj. \u0130\u00e7in Liyofilize Toz \u0130\u00e7eren Flakon, Ber\u0131nert P IV Enjeksiyonluk \u00c7\u00f6zelti \u0130\u00e7in Toz ve \u00c7\u00f6z\u00fcc\u00fc 500 Iu\/10 Ml 1 Flakon)<\/span><\/p>\n

v  <\/span><\/span>Vazopressin geri \u00f6denme ko\u015fullar\u0131 d\u00fczenlendi.<\/span><\/p>\n

\n
\n  
\n <\/o:p>v  <\/span><\/span>Vedolizumab (Entyv\u0131o \u0130nf\u00fczyonluk \u00c7\u00f6zelti Konsantresi \u0130\u00e7in Toz) etkin maddesinin ayaktan tedavide kar\u015f\u0131lanmas\u0131 sa\u011fland\u0131. <\/span><\/p>\n

02.11.2024_SUT_KAR\u015eILA\u015eTIRMALI TABLO 06.11.2024.pdf<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"

02.11.2024 Tarihli SUT De\u011fi\u015fikli\u011fi Hakk\u0131nda Bilgi Notu   A\u015fa\u011f\u0131da yer alan d\u00fczenlemeler, 09 Kas\u0131m 2024 tarihinde y\u00fcr\u00fcrl\u00fc\u011fe girecektir.   v  SUT\u2019un 2.4.3-B maddesinde yap\u0131lan de\u011fi\u015fiklik ile, grip a\u015f\u0131s\u0131 bedelinin her Eyl\u00fcl ila Mart d\u00f6nemleri i\u00e7erisinde re\u00e7ete edildi\u011finde bir defaya mahsus olmak \u00fczere kar\u015f\u0131lanaca\u011f\u0131 d\u00fczenlendi.  v  SUT\u2019un 4.2.1 maddesine bimekizumab (B\u0131mzelx 160 Mg\/Ml SC Enjeksiyonluk \u00c7\u00f6zelti \u0130\u00e7eren Kullan\u0131ma Haz\u0131r Kalem) etkin maddesi eklenerek, geri \u00f6denme ko\u015fullar\u0131 belirlendi.   v  Biyolojik ajanlar i\u00e7in ara verme kriterleri belirlendi. Bu s\u00fcre; Rituksimab (Mabthera flakon) i\u00e7in 12 ay, di\u011fer biyolojik ajanlar i\u00e7in 6 ay olarak belirlendi.   v  Biyolojik ajanlarda, etkisizlik veya yan etki nedeniyle ila\u00e7 de\u011fi\u015fimi durumunda tedaviye ba\u015flang\u0131\u00e7 dozu ile devam edilece\u011fi konusu netle\u015ftirildi.   v  Ayn\u0131 hasta i\u00e7in iki farkl\u0131 tan\u0131 ile iki farkl\u0131 anti-TNF veya biyolojik ajan\u0131n birlikte kullan\u0131lmas\u0131 halinde bedellerinin Kurumca kar\u015f\u0131lanmayaca\u011f\u0131 d\u00fczenlendi.   v  Biyolojik ajan tedavi basamaklar\u0131nda de\u011fi\u015fiklik yap\u0131lmas\u0131 halinde, tedavinin ba\u015fland\u0131\u011f\u0131 tarihteki Sa\u011fl\u0131k Uygulama Tebli\u011finde yer alan ba\u015flang\u0131\u00e7 kriterleri ge\u00e7erli olup, bu konudaki teredd\u00fctler giderildi.   v  \u00dclseratif Kolit hastal\u0131\u011f\u0131nda ba\u015flang\u0131\u00e7 rapor s\u00fcreleri 4 ay, idame rapor s\u00fcreleri 6 ay olarak d\u00fczenlendi.   v  Tofacitinib (Xeljanz Film Tablet, Jandark Film Kapl\u0131 Tablet) etkin maddesinin Poliartik\u00fcler Juvenil \u0130diyopatik Artriti (PJ\u0130A) tan\u0131s\u0131nda geri \u00f6denme ko\u015fullar\u0131 belirlendi.   v  Kanakinumab (Ilar\u0131s Enjeksiyonluk \u00c7\u00f6zelti \u0130\u00e7in Toz \u0130\u00e7eren Flakon) etkin maddesinin (T\u00fcm\u00f6r nekroz edici fakt\u00f6r resept\u00f6r\u00fc 1 ile ili\u015fkili periyodik ate\u015f sendromlar\u0131) TRAPS, (Hiper\u0130mm\u00fcnglob\u00fclin D Sendromu) HIDS ve (Mevalonat Kinaz eksikli\u011fi) MKD tan\u0131lar\u0131nda geri \u00f6denme ko\u015fullar\u0131 belirlendi.   v  Lamotrijin (Lam\u0131ctal DC \u00c7\u00f6z\u00fcn\u00fcr\/\u00c7i\u011fneme Tableti) etkin maddesinin, bipolar bozukluk endikasyonunda psikiyatri uzman hekimleri taraf\u0131ndan veya bu hekimlerce d\u00fczenlenen uzman hekim raporuna dayan\u0131larak t\u00fcm hekimlerce re\u00e7ete edilebilece\u011fi d\u00fczenlendi.   v  D\u00fc\u015f\u00fck molek\u00fcl a\u011f\u0131rl\u0131kl\u0131 heparinlerde (DMAH) 1 y\u0131ldan uzun s\u00fcreli kullan\u0131mda; onkoloji, hematoloji, kalp damar cerrahisi, kardiyoloji, g\u00f6\u011f\u00fcs hastal\u0131klar\u0131 veya n\u00f6roloji uzman hekimlerinden herhangi birinin bulundu\u011fu sa\u011fl\u0131k kurulu raporuna istinaden t\u00fcm hekimlerce re\u00e7ete edilmesi halinde bedellerinin Kurumca kar\u015f\u0131lanaca\u011f\u0131 d\u00fczenlendi.   v  Spesifik olmayan imm\u00fcnglobulinlerin geri \u00f6denme ko\u015fullar\u0131, IV veya IV \/ SC ile uygulama yolu sadece SC olarak ikiye ayr\u0131ld\u0131. Primer immun yetmezli\u011fi tan\u0131s\u0131nda yaln\u0131zca sa\u011fl\u0131k kurulu raporu ile geri \u00f6deme kapsam\u0131 d\u00fczenlendi.   v  Akut Hepatit B tedavisinde antivirallerin \u00f6denme ko\u015fullar\u0131 belirlendi. Kronik Hepatit B tedavisine ili\u015fkin biyopsi ve benzeri kriterlerde de\u011fi\u015fiklik yap\u0131ld\u0131.   v  Koloni Uyar\u0131c\u0131 Fakt\u00f6rler olan filgrastim (Neupogen Roche Haz\u0131r \u015e\u0131r\u0131nga), lenograstim (Granocyte Enjeksiyonluk\/Inf\u00fczyonluk Liyofilize Toz \u0130\u00e7eren Flakon), pegfilgrastim (Neulast\u0131m S.C. Enjeksiyon \u0130\u00e7in Kullan\u0131ma Haz\u0131r \u015e\u0131r\u0131nga) ve lipegfilgrastim (Lonquex Kullan\u0131ma Haz\u0131r Dolu Enjektor) etkin maddeleri i\u00e7in, re\u00e7ete ve rapor d\u00fczenleyebilecek bran\u015flar d\u00fczenlendi.   v  \u00d6zel d\u00fczenleme yap\u0131lan ve kanser tedavisinde kullan\u0131lan baz\u0131 etkin maddelerin geri \u00f6denme ko\u015fullar\u0131na d\u00fczenlemeler ve eklemeler yap\u0131ld\u0131.   v  Ranolazin (Lat\u0131xa Uzat\u0131lm\u0131\u015f Sal\u0131ml\u0131 Tablet) etkin maddesi i\u00e7in d\u00fczenlenecek rapor s\u00fcresi 2 y\u0131la \u00e7\u0131kar\u0131ld\u0131.   v  T\u0131bbi mamalar\u0131n, kronik b\u00f6brek hastal\u0131\u011f\u0131 (evre 2-5) tan\u0131s\u0131 olan 3 ya\u015f ve \u00fczeri \u00e7ocuklarda geri \u00f6denme ko\u015fullar\u0131 belirlendi.   v  Pregabalin (Lyr\u0131ca Kaps\u00fcl) ve gabapentin (Gabaset Kapsul) etkin maddeleri i\u00e7in, ikinci ve \u00fc\u00e7\u00fcnc\u00fc basamak sa\u011fl\u0131k hizmeti sunucular\u0131nda rapor d\u00fczenlenmesi sa\u011fland\u0131. Ayr\u0131ca pregabalin (Lyr\u0131ca Kaps\u00fcl) etkin maddesinin kronik kas iskelet a\u011fr\u0131s\u0131 ile fibromiyaljide ikinci ve \u00fc\u00e7\u00fcnc\u00fc basamak sa\u011fl\u0131k kurumlar\u0131nda rapor d\u00fczenlenmesi sa\u011flanarak, bran\u015flar aras\u0131na n\u00f6roloji eklendi.   v  Fakt\u00f6r kullan\u0131m\u0131 i\u00e7in, ilk raporun \u00fc\u00e7\u00fcnc\u00fc basamak resmi sa\u011fl\u0131k hizmeti sunucular\u0131nda d\u00fczenlenme zorunlulu\u011fu getirildi.   v  Kontrast maddelerin geri \u00f6denme ko\u015fullar\u0131 d\u00fczenlendi ve kontrast maddenin t\u00fcr\u00fcne g\u00f6re kar\u015f\u0131lanabilecek kutu say\u0131lar\u0131 belirlendi.   v  Ranibizumab (Lucentis) etkin maddesinin premat\u00fcre retinopatisi tedavisinde geri \u00f6denme ko\u015fullar\u0131 belirlendi.   v  Anti-VEGF ila\u00e7larda ila\u00e7 de\u011fi\u015fimi gereken idame tedavilerde, y\u00fckleme dozu aranmas\u0131 zorunlulu\u011fu kald\u0131r\u0131ld\u0131.   v  Parenteral demir preparatlar\u0131nda geri \u00f6deme ko\u015fullar\u0131na demir eksikli\u011fi tedavisine ili\u015fkin ibare eklendi.   v  Gonadotropin kullan\u0131m ilkelerinde, kombine FSH-LH preparatlar\u0131 ile koryogonadotropin alfa etkin maddeli ila\u00e7lar\u0131n kombine kullan\u0131m\u0131n\u0131n engellenmesine y\u00f6nelik d\u00fczenleme yap\u0131ld\u0131. \u00d6rnek olarak, Menagon ve Ovitrelle birlikte kar\u015f\u0131lanmaz.   v  Daratumumab (Darzalex) etkin maddesinin Amiloidoz hastal\u0131\u011f\u0131nda geri \u00f6denme ko\u015fullar\u0131 belirlendi.   v  Dupilumab (Dupixent) etkin maddesi i\u00e7in endikasyon uyumu zorunlulu\u011fu getirildi.   v  Sefaklor (Cec Efervesan Tablet) etkin maddesinin efervesan formlar\u0131n\u0131n enfeksiyon hastal\u0131klar\u0131 uzman\u0131 taraf\u0131ndan re\u00e7ete edilebilece\u011fi d\u00fczenlendi.   v  \u0130vermektin (Ziver) etkin maddesinin, K\u0131sa \u00dcr\u00fcn Bilgisinde (K\u00dcB) yer alan pozolojisini a\u015fmayacak dozda re\u00e7etelenece\u011fi d\u00fczenlendi.   v  C1-esteraz inhibit\u00f6rleri i\u00e7in geri \u00f6denme ko\u015fullar\u0131 d\u00fczenlendi. (C\u0131nryze Iv Enj. \u0130\u00e7in Liyofilize Toz \u0130\u00e7eren Flakon, Ber\u0131nert P IV Enjeksiyonluk \u00c7\u00f6zelti \u0130\u00e7in Toz ve \u00c7\u00f6z\u00fcc\u00fc 500 Iu\/10 Ml 1 Flakon) v  Vazopressin geri \u00f6denme ko\u015fullar\u0131 d\u00fczenlendi.   v  Vedolizumab (Entyv\u0131o \u0130nf\u00fczyonluk \u00c7\u00f6zelti Konsantresi \u0130\u00e7in Toz) etkin maddesinin ayaktan tedavide kar\u015f\u0131lanmas\u0131 sa\u011fland\u0131.  02.11.2024_SUT_KAR\u015eILA\u015eTIRMALI TABLO 06.11.2024.pdf<\/p>\n","protected":false},"author":4,"featured_media":191,"comment_status":"open","ping_status":"open","sticky":false,"template":"elementor_canvas","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-5347","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-oda"],"yoast_head":"\nSUT DE\u011e\u0130\u015e\u0130KL\u0130\u011e\u0130 HK. - \u015eanl\u0131urfa Eczac\u0131 Odas\u0131<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/2024\/11\/06\/sut-degisikligi-hk\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SUT DE\u011e\u0130\u015e\u0130KL\u0130\u011e\u0130 HK. - \u015eanl\u0131urfa Eczac\u0131 Odas\u0131\" \/>\n<meta property=\"og:description\" content=\"02.11.2024 Tarihli SUT De\u011fi\u015fikli\u011fi Hakk\u0131nda Bilgi Notu   A\u015fa\u011f\u0131da yer alan d\u00fczenlemeler, 09 Kas\u0131m 2024 tarihinde y\u00fcr\u00fcrl\u00fc\u011fe girecektir.   v  SUT\u2019un 2.4.3-B maddesinde yap\u0131lan de\u011fi\u015fiklik ile, grip a\u015f\u0131s\u0131 bedelinin her Eyl\u00fcl ila Mart d\u00f6nemleri i\u00e7erisinde re\u00e7ete edildi\u011finde bir defaya mahsus olmak \u00fczere kar\u015f\u0131lanaca\u011f\u0131 d\u00fczenlendi.  v  SUT\u2019un 4.2.1 maddesine bimekizumab (B\u0131mzelx 160 Mg\/Ml SC Enjeksiyonluk \u00c7\u00f6zelti \u0130\u00e7eren Kullan\u0131ma Haz\u0131r Kalem) etkin maddesi eklenerek, geri \u00f6denme ko\u015fullar\u0131 belirlendi.   v  Biyolojik ajanlar i\u00e7in ara verme kriterleri belirlendi. Bu s\u00fcre; Rituksimab (Mabthera flakon) i\u00e7in 12 ay, di\u011fer biyolojik ajanlar i\u00e7in 6 ay olarak belirlendi.   v  Biyolojik ajanlarda, etkisizlik veya yan etki nedeniyle ila\u00e7 de\u011fi\u015fimi durumunda tedaviye ba\u015flang\u0131\u00e7 dozu ile devam edilece\u011fi konusu netle\u015ftirildi.   v  Ayn\u0131 hasta i\u00e7in iki farkl\u0131 tan\u0131 ile iki farkl\u0131 anti-TNF veya biyolojik ajan\u0131n birlikte kullan\u0131lmas\u0131 halinde bedellerinin Kurumca kar\u015f\u0131lanmayaca\u011f\u0131 d\u00fczenlendi.   v  Biyolojik ajan tedavi basamaklar\u0131nda de\u011fi\u015fiklik yap\u0131lmas\u0131 halinde, tedavinin ba\u015fland\u0131\u011f\u0131 tarihteki Sa\u011fl\u0131k Uygulama Tebli\u011finde yer alan ba\u015flang\u0131\u00e7 kriterleri ge\u00e7erli olup, bu konudaki teredd\u00fctler giderildi.   v  \u00dclseratif Kolit hastal\u0131\u011f\u0131nda ba\u015flang\u0131\u00e7 rapor s\u00fcreleri 4 ay, idame rapor s\u00fcreleri 6 ay olarak d\u00fczenlendi.   v  Tofacitinib (Xeljanz Film Tablet, Jandark Film Kapl\u0131 Tablet) etkin maddesinin Poliartik\u00fcler Juvenil \u0130diyopatik Artriti (PJ\u0130A) tan\u0131s\u0131nda geri \u00f6denme ko\u015fullar\u0131 belirlendi.   v  Kanakinumab (Ilar\u0131s Enjeksiyonluk \u00c7\u00f6zelti \u0130\u00e7in Toz \u0130\u00e7eren Flakon) etkin maddesinin (T\u00fcm\u00f6r nekroz edici fakt\u00f6r resept\u00f6r\u00fc 1 ile ili\u015fkili periyodik ate\u015f sendromlar\u0131) TRAPS, (Hiper\u0130mm\u00fcnglob\u00fclin D Sendromu) HIDS ve (Mevalonat Kinaz eksikli\u011fi) MKD tan\u0131lar\u0131nda geri \u00f6denme ko\u015fullar\u0131 belirlendi.   v  Lamotrijin (Lam\u0131ctal DC \u00c7\u00f6z\u00fcn\u00fcr\/\u00c7i\u011fneme Tableti) etkin maddesinin, bipolar bozukluk endikasyonunda psikiyatri uzman hekimleri taraf\u0131ndan veya bu hekimlerce d\u00fczenlenen uzman hekim raporuna dayan\u0131larak t\u00fcm hekimlerce re\u00e7ete edilebilece\u011fi d\u00fczenlendi.   v  D\u00fc\u015f\u00fck molek\u00fcl a\u011f\u0131rl\u0131kl\u0131 heparinlerde (DMAH) 1 y\u0131ldan uzun s\u00fcreli kullan\u0131mda; onkoloji, hematoloji, kalp damar cerrahisi, kardiyoloji, g\u00f6\u011f\u00fcs hastal\u0131klar\u0131 veya n\u00f6roloji uzman hekimlerinden herhangi birinin bulundu\u011fu sa\u011fl\u0131k kurulu raporuna istinaden t\u00fcm hekimlerce re\u00e7ete edilmesi halinde bedellerinin Kurumca kar\u015f\u0131lanaca\u011f\u0131 d\u00fczenlendi.   v  Spesifik olmayan imm\u00fcnglobulinlerin geri \u00f6denme ko\u015fullar\u0131, IV veya IV \/ SC ile uygulama yolu sadece SC olarak ikiye ayr\u0131ld\u0131. Primer immun yetmezli\u011fi tan\u0131s\u0131nda yaln\u0131zca sa\u011fl\u0131k kurulu raporu ile geri \u00f6deme kapsam\u0131 d\u00fczenlendi.   v  Akut Hepatit B tedavisinde antivirallerin \u00f6denme ko\u015fullar\u0131 belirlendi. Kronik Hepatit B tedavisine ili\u015fkin biyopsi ve benzeri kriterlerde de\u011fi\u015fiklik yap\u0131ld\u0131.   v  Koloni Uyar\u0131c\u0131 Fakt\u00f6rler olan filgrastim (Neupogen Roche Haz\u0131r \u015e\u0131r\u0131nga), lenograstim (Granocyte Enjeksiyonluk\/Inf\u00fczyonluk Liyofilize Toz \u0130\u00e7eren Flakon), pegfilgrastim (Neulast\u0131m S.C. Enjeksiyon \u0130\u00e7in Kullan\u0131ma Haz\u0131r \u015e\u0131r\u0131nga) ve lipegfilgrastim (Lonquex Kullan\u0131ma Haz\u0131r Dolu Enjektor) etkin maddeleri i\u00e7in, re\u00e7ete ve rapor d\u00fczenleyebilecek bran\u015flar d\u00fczenlendi.   v  \u00d6zel d\u00fczenleme yap\u0131lan ve kanser tedavisinde kullan\u0131lan baz\u0131 etkin maddelerin geri \u00f6denme ko\u015fullar\u0131na d\u00fczenlemeler ve eklemeler yap\u0131ld\u0131.   v  Ranolazin (Lat\u0131xa Uzat\u0131lm\u0131\u015f Sal\u0131ml\u0131 Tablet) etkin maddesi i\u00e7in d\u00fczenlenecek rapor s\u00fcresi 2 y\u0131la \u00e7\u0131kar\u0131ld\u0131.   v  T\u0131bbi mamalar\u0131n, kronik b\u00f6brek hastal\u0131\u011f\u0131 (evre 2-5) tan\u0131s\u0131 olan 3 ya\u015f ve \u00fczeri \u00e7ocuklarda geri \u00f6denme ko\u015fullar\u0131 belirlendi.   v  Pregabalin (Lyr\u0131ca Kaps\u00fcl) ve gabapentin (Gabaset Kapsul) etkin maddeleri i\u00e7in, ikinci ve \u00fc\u00e7\u00fcnc\u00fc basamak sa\u011fl\u0131k hizmeti sunucular\u0131nda rapor d\u00fczenlenmesi sa\u011fland\u0131. Ayr\u0131ca pregabalin (Lyr\u0131ca Kaps\u00fcl) etkin maddesinin kronik kas iskelet a\u011fr\u0131s\u0131 ile fibromiyaljide ikinci ve \u00fc\u00e7\u00fcnc\u00fc basamak sa\u011fl\u0131k kurumlar\u0131nda rapor d\u00fczenlenmesi sa\u011flanarak, bran\u015flar aras\u0131na n\u00f6roloji eklendi.   v  Fakt\u00f6r kullan\u0131m\u0131 i\u00e7in, ilk raporun \u00fc\u00e7\u00fcnc\u00fc basamak resmi sa\u011fl\u0131k hizmeti sunucular\u0131nda d\u00fczenlenme zorunlulu\u011fu getirildi.   v  Kontrast maddelerin geri \u00f6denme ko\u015fullar\u0131 d\u00fczenlendi ve kontrast maddenin t\u00fcr\u00fcne g\u00f6re kar\u015f\u0131lanabilecek kutu say\u0131lar\u0131 belirlendi.   v  Ranibizumab (Lucentis) etkin maddesinin premat\u00fcre retinopatisi tedavisinde geri \u00f6denme ko\u015fullar\u0131 belirlendi.   v  Anti-VEGF ila\u00e7larda ila\u00e7 de\u011fi\u015fimi gereken idame tedavilerde, y\u00fckleme dozu aranmas\u0131 zorunlulu\u011fu kald\u0131r\u0131ld\u0131.   v  Parenteral demir preparatlar\u0131nda geri \u00f6deme ko\u015fullar\u0131na demir eksikli\u011fi tedavisine ili\u015fkin ibare eklendi.   v  Gonadotropin kullan\u0131m ilkelerinde, kombine FSH-LH preparatlar\u0131 ile koryogonadotropin alfa etkin maddeli ila\u00e7lar\u0131n kombine kullan\u0131m\u0131n\u0131n engellenmesine y\u00f6nelik d\u00fczenleme yap\u0131ld\u0131. \u00d6rnek olarak, Menagon ve Ovitrelle birlikte kar\u015f\u0131lanmaz.   v  Daratumumab (Darzalex) etkin maddesinin Amiloidoz hastal\u0131\u011f\u0131nda geri \u00f6denme ko\u015fullar\u0131 belirlendi.   v  Dupilumab (Dupixent) etkin maddesi i\u00e7in endikasyon uyumu zorunlulu\u011fu getirildi.   v  Sefaklor (Cec Efervesan Tablet) etkin maddesinin efervesan formlar\u0131n\u0131n enfeksiyon hastal\u0131klar\u0131 uzman\u0131 taraf\u0131ndan re\u00e7ete edilebilece\u011fi d\u00fczenlendi.   v  \u0130vermektin (Ziver) etkin maddesinin, K\u0131sa \u00dcr\u00fcn Bilgisinde (K\u00dcB) yer alan pozolojisini a\u015fmayacak dozda re\u00e7etelenece\u011fi d\u00fczenlendi.   v  C1-esteraz inhibit\u00f6rleri i\u00e7in geri \u00f6denme ko\u015fullar\u0131 d\u00fczenlendi. (C\u0131nryze Iv Enj. \u0130\u00e7in Liyofilize Toz \u0130\u00e7eren Flakon, Ber\u0131nert P IV Enjeksiyonluk \u00c7\u00f6zelti \u0130\u00e7in Toz ve \u00c7\u00f6z\u00fcc\u00fc 500 Iu\/10 Ml 1 Flakon) v  Vazopressin geri \u00f6denme ko\u015fullar\u0131 d\u00fczenlendi.   v  Vedolizumab (Entyv\u0131o \u0130nf\u00fczyonluk \u00c7\u00f6zelti Konsantresi \u0130\u00e7in Toz) etkin maddesinin ayaktan tedavide kar\u015f\u0131lanmas\u0131 sa\u011fland\u0131.  02.11.2024_SUT_KAR\u015eILA\u015eTIRMALI TABLO 06.11.2024.pdf\" \/>\n<meta property=\"og:url\" content=\"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/2024\/11\/06\/sut-degisikligi-hk\/\" \/>\n<meta property=\"og:site_name\" content=\"\u015eanl\u0131urfa Eczac\u0131 Odas\u0131\" \/>\n<meta property=\"article:published_time\" content=\"2024-11-06T09:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-19T08:12:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/sanliurfaeo.birodam.org.tr\/wp-content\/uploads\/2025\/09\/urfaeo-logo2.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"768\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Yeni Admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Yeni Admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tahmini okuma s\u00fcresi\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 dakika\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/index.php\\\/2024\\\/11\\\/06\\\/sut-degisikligi-hk\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/index.php\\\/2024\\\/11\\\/06\\\/sut-degisikligi-hk\\\/\"},\"author\":{\"name\":\"Yeni Admin\",\"@id\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/#\\\/schema\\\/person\\\/f482a8288e46359eb9acced6151e1120\"},\"headline\":\"SUT DE\u011e\u0130\u015e\u0130KL\u0130\u011e\u0130 HK.\",\"datePublished\":\"2024-11-06T09:00:00+00:00\",\"dateModified\":\"2026-01-19T08:12:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/index.php\\\/2024\\\/11\\\/06\\\/sut-degisikligi-hk\\\/\"},\"wordCount\":994,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/index.php\\\/2024\\\/11\\\/06\\\/sut-degisikligi-hk\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/urfaeo-logo2.png\",\"articleSection\":[\"ODA\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/index.php\\\/2024\\\/11\\\/06\\\/sut-degisikligi-hk\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/index.php\\\/2024\\\/11\\\/06\\\/sut-degisikligi-hk\\\/\",\"url\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/index.php\\\/2024\\\/11\\\/06\\\/sut-degisikligi-hk\\\/\",\"name\":\"SUT DE\u011e\u0130\u015e\u0130KL\u0130\u011e\u0130 HK. - \u015eanl\u0131urfa Eczac\u0131 Odas\u0131\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/index.php\\\/2024\\\/11\\\/06\\\/sut-degisikligi-hk\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/index.php\\\/2024\\\/11\\\/06\\\/sut-degisikligi-hk\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/urfaeo-logo2.png\",\"datePublished\":\"2024-11-06T09:00:00+00:00\",\"dateModified\":\"2026-01-19T08:12:07+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/index.php\\\/2024\\\/11\\\/06\\\/sut-degisikligi-hk\\\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/index.php\\\/2024\\\/11\\\/06\\\/sut-degisikligi-hk\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/index.php\\\/2024\\\/11\\\/06\\\/sut-degisikligi-hk\\\/#primaryimage\",\"url\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/urfaeo-logo2.png\",\"contentUrl\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/urfaeo-logo2.png\",\"width\":1024,\"height\":768},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/index.php\\\/2024\\\/11\\\/06\\\/sut-degisikligi-hk\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Anasayfa\",\"item\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SUT DE\u011e\u0130\u015e\u0130KL\u0130\u011e\u0130 HK.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/#website\",\"url\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/\",\"name\":\"\u015eanl\u0131urfa Eczac\u0131 Odas\u0131\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/#organization\",\"name\":\"\u015eanl\u0131urfa Eczac\u0131 Odas\u0131\",\"url\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/22022021211638-19929-73208.png\",\"contentUrl\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/22022021211638-19929-73208.png\",\"width\":635,\"height\":635,\"caption\":\"\u015eanl\u0131urfa Eczac\u0131 Odas\u0131\"},\"image\":{\"@id\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/#\\\/schema\\\/person\\\/f482a8288e46359eb9acced6151e1120\",\"name\":\"Yeni Admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b1bcfc5d55af4e7fc9737f956325e8d9203056464179614b915004d0d1be29d3?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b1bcfc5d55af4e7fc9737f956325e8d9203056464179614b915004d0d1be29d3?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b1bcfc5d55af4e7fc9737f956325e8d9203056464179614b915004d0d1be29d3?s=96&d=mm&r=g\",\"caption\":\"Yeni Admin\"},\"url\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/index.php\\\/author\\\/yeniadmin\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SUT DE\u011e\u0130\u015e\u0130KL\u0130\u011e\u0130 HK. - \u015eanl\u0131urfa Eczac\u0131 Odas\u0131","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/2024\/11\/06\/sut-degisikligi-hk\/","og_locale":"tr_TR","og_type":"article","og_title":"SUT DE\u011e\u0130\u015e\u0130KL\u0130\u011e\u0130 HK. - \u015eanl\u0131urfa Eczac\u0131 Odas\u0131","og_description":"02.11.2024 Tarihli SUT De\u011fi\u015fikli\u011fi Hakk\u0131nda Bilgi Notu   A\u015fa\u011f\u0131da yer alan d\u00fczenlemeler, 09 Kas\u0131m 2024 tarihinde y\u00fcr\u00fcrl\u00fc\u011fe girecektir.   v  SUT\u2019un 2.4.3-B maddesinde yap\u0131lan de\u011fi\u015fiklik ile, grip a\u015f\u0131s\u0131 bedelinin her Eyl\u00fcl ila Mart d\u00f6nemleri i\u00e7erisinde re\u00e7ete edildi\u011finde bir defaya mahsus olmak \u00fczere kar\u015f\u0131lanaca\u011f\u0131 d\u00fczenlendi.  v  SUT\u2019un 4.2.1 maddesine bimekizumab (B\u0131mzelx 160 Mg\/Ml SC Enjeksiyonluk \u00c7\u00f6zelti \u0130\u00e7eren Kullan\u0131ma Haz\u0131r Kalem) etkin maddesi eklenerek, geri \u00f6denme ko\u015fullar\u0131 belirlendi.   v  Biyolojik ajanlar i\u00e7in ara verme kriterleri belirlendi. Bu s\u00fcre; Rituksimab (Mabthera flakon) i\u00e7in 12 ay, di\u011fer biyolojik ajanlar i\u00e7in 6 ay olarak belirlendi.   v  Biyolojik ajanlarda, etkisizlik veya yan etki nedeniyle ila\u00e7 de\u011fi\u015fimi durumunda tedaviye ba\u015flang\u0131\u00e7 dozu ile devam edilece\u011fi konusu netle\u015ftirildi.   v  Ayn\u0131 hasta i\u00e7in iki farkl\u0131 tan\u0131 ile iki farkl\u0131 anti-TNF veya biyolojik ajan\u0131n birlikte kullan\u0131lmas\u0131 halinde bedellerinin Kurumca kar\u015f\u0131lanmayaca\u011f\u0131 d\u00fczenlendi.   v  Biyolojik ajan tedavi basamaklar\u0131nda de\u011fi\u015fiklik yap\u0131lmas\u0131 halinde, tedavinin ba\u015fland\u0131\u011f\u0131 tarihteki Sa\u011fl\u0131k Uygulama Tebli\u011finde yer alan ba\u015flang\u0131\u00e7 kriterleri ge\u00e7erli olup, bu konudaki teredd\u00fctler giderildi.   v  \u00dclseratif Kolit hastal\u0131\u011f\u0131nda ba\u015flang\u0131\u00e7 rapor s\u00fcreleri 4 ay, idame rapor s\u00fcreleri 6 ay olarak d\u00fczenlendi.   v  Tofacitinib (Xeljanz Film Tablet, Jandark Film Kapl\u0131 Tablet) etkin maddesinin Poliartik\u00fcler Juvenil \u0130diyopatik Artriti (PJ\u0130A) tan\u0131s\u0131nda geri \u00f6denme ko\u015fullar\u0131 belirlendi.   v  Kanakinumab (Ilar\u0131s Enjeksiyonluk \u00c7\u00f6zelti \u0130\u00e7in Toz \u0130\u00e7eren Flakon) etkin maddesinin (T\u00fcm\u00f6r nekroz edici fakt\u00f6r resept\u00f6r\u00fc 1 ile ili\u015fkili periyodik ate\u015f sendromlar\u0131) TRAPS, (Hiper\u0130mm\u00fcnglob\u00fclin D Sendromu) HIDS ve (Mevalonat Kinaz eksikli\u011fi) MKD tan\u0131lar\u0131nda geri \u00f6denme ko\u015fullar\u0131 belirlendi.   v  Lamotrijin (Lam\u0131ctal DC \u00c7\u00f6z\u00fcn\u00fcr\/\u00c7i\u011fneme Tableti) etkin maddesinin, bipolar bozukluk endikasyonunda psikiyatri uzman hekimleri taraf\u0131ndan veya bu hekimlerce d\u00fczenlenen uzman hekim raporuna dayan\u0131larak t\u00fcm hekimlerce re\u00e7ete edilebilece\u011fi d\u00fczenlendi.   v  D\u00fc\u015f\u00fck molek\u00fcl a\u011f\u0131rl\u0131kl\u0131 heparinlerde (DMAH) 1 y\u0131ldan uzun s\u00fcreli kullan\u0131mda; onkoloji, hematoloji, kalp damar cerrahisi, kardiyoloji, g\u00f6\u011f\u00fcs hastal\u0131klar\u0131 veya n\u00f6roloji uzman hekimlerinden herhangi birinin bulundu\u011fu sa\u011fl\u0131k kurulu raporuna istinaden t\u00fcm hekimlerce re\u00e7ete edilmesi halinde bedellerinin Kurumca kar\u015f\u0131lanaca\u011f\u0131 d\u00fczenlendi.   v  Spesifik olmayan imm\u00fcnglobulinlerin geri \u00f6denme ko\u015fullar\u0131, IV veya IV \/ SC ile uygulama yolu sadece SC olarak ikiye ayr\u0131ld\u0131. Primer immun yetmezli\u011fi tan\u0131s\u0131nda yaln\u0131zca sa\u011fl\u0131k kurulu raporu ile geri \u00f6deme kapsam\u0131 d\u00fczenlendi.   v  Akut Hepatit B tedavisinde antivirallerin \u00f6denme ko\u015fullar\u0131 belirlendi. Kronik Hepatit B tedavisine ili\u015fkin biyopsi ve benzeri kriterlerde de\u011fi\u015fiklik yap\u0131ld\u0131.   v  Koloni Uyar\u0131c\u0131 Fakt\u00f6rler olan filgrastim (Neupogen Roche Haz\u0131r \u015e\u0131r\u0131nga), lenograstim (Granocyte Enjeksiyonluk\/Inf\u00fczyonluk Liyofilize Toz \u0130\u00e7eren Flakon), pegfilgrastim (Neulast\u0131m S.C. Enjeksiyon \u0130\u00e7in Kullan\u0131ma Haz\u0131r \u015e\u0131r\u0131nga) ve lipegfilgrastim (Lonquex Kullan\u0131ma Haz\u0131r Dolu Enjektor) etkin maddeleri i\u00e7in, re\u00e7ete ve rapor d\u00fczenleyebilecek bran\u015flar d\u00fczenlendi.   v  \u00d6zel d\u00fczenleme yap\u0131lan ve kanser tedavisinde kullan\u0131lan baz\u0131 etkin maddelerin geri \u00f6denme ko\u015fullar\u0131na d\u00fczenlemeler ve eklemeler yap\u0131ld\u0131.   v  Ranolazin (Lat\u0131xa Uzat\u0131lm\u0131\u015f Sal\u0131ml\u0131 Tablet) etkin maddesi i\u00e7in d\u00fczenlenecek rapor s\u00fcresi 2 y\u0131la \u00e7\u0131kar\u0131ld\u0131.   v  T\u0131bbi mamalar\u0131n, kronik b\u00f6brek hastal\u0131\u011f\u0131 (evre 2-5) tan\u0131s\u0131 olan 3 ya\u015f ve \u00fczeri \u00e7ocuklarda geri \u00f6denme ko\u015fullar\u0131 belirlendi.   v  Pregabalin (Lyr\u0131ca Kaps\u00fcl) ve gabapentin (Gabaset Kapsul) etkin maddeleri i\u00e7in, ikinci ve \u00fc\u00e7\u00fcnc\u00fc basamak sa\u011fl\u0131k hizmeti sunucular\u0131nda rapor d\u00fczenlenmesi sa\u011fland\u0131. Ayr\u0131ca pregabalin (Lyr\u0131ca Kaps\u00fcl) etkin maddesinin kronik kas iskelet a\u011fr\u0131s\u0131 ile fibromiyaljide ikinci ve \u00fc\u00e7\u00fcnc\u00fc basamak sa\u011fl\u0131k kurumlar\u0131nda rapor d\u00fczenlenmesi sa\u011flanarak, bran\u015flar aras\u0131na n\u00f6roloji eklendi.   v  Fakt\u00f6r kullan\u0131m\u0131 i\u00e7in, ilk raporun \u00fc\u00e7\u00fcnc\u00fc basamak resmi sa\u011fl\u0131k hizmeti sunucular\u0131nda d\u00fczenlenme zorunlulu\u011fu getirildi.   v  Kontrast maddelerin geri \u00f6denme ko\u015fullar\u0131 d\u00fczenlendi ve kontrast maddenin t\u00fcr\u00fcne g\u00f6re kar\u015f\u0131lanabilecek kutu say\u0131lar\u0131 belirlendi.   v  Ranibizumab (Lucentis) etkin maddesinin premat\u00fcre retinopatisi tedavisinde geri \u00f6denme ko\u015fullar\u0131 belirlendi.   v  Anti-VEGF ila\u00e7larda ila\u00e7 de\u011fi\u015fimi gereken idame tedavilerde, y\u00fckleme dozu aranmas\u0131 zorunlulu\u011fu kald\u0131r\u0131ld\u0131.   v  Parenteral demir preparatlar\u0131nda geri \u00f6deme ko\u015fullar\u0131na demir eksikli\u011fi tedavisine ili\u015fkin ibare eklendi.   v  Gonadotropin kullan\u0131m ilkelerinde, kombine FSH-LH preparatlar\u0131 ile koryogonadotropin alfa etkin maddeli ila\u00e7lar\u0131n kombine kullan\u0131m\u0131n\u0131n engellenmesine y\u00f6nelik d\u00fczenleme yap\u0131ld\u0131. \u00d6rnek olarak, Menagon ve Ovitrelle birlikte kar\u015f\u0131lanmaz.   v  Daratumumab (Darzalex) etkin maddesinin Amiloidoz hastal\u0131\u011f\u0131nda geri \u00f6denme ko\u015fullar\u0131 belirlendi.   v  Dupilumab (Dupixent) etkin maddesi i\u00e7in endikasyon uyumu zorunlulu\u011fu getirildi.   v  Sefaklor (Cec Efervesan Tablet) etkin maddesinin efervesan formlar\u0131n\u0131n enfeksiyon hastal\u0131klar\u0131 uzman\u0131 taraf\u0131ndan re\u00e7ete edilebilece\u011fi d\u00fczenlendi.   v  \u0130vermektin (Ziver) etkin maddesinin, K\u0131sa \u00dcr\u00fcn Bilgisinde (K\u00dcB) yer alan pozolojisini a\u015fmayacak dozda re\u00e7etelenece\u011fi d\u00fczenlendi.   v  C1-esteraz inhibit\u00f6rleri i\u00e7in geri \u00f6denme ko\u015fullar\u0131 d\u00fczenlendi. (C\u0131nryze Iv Enj. \u0130\u00e7in Liyofilize Toz \u0130\u00e7eren Flakon, Ber\u0131nert P IV Enjeksiyonluk \u00c7\u00f6zelti \u0130\u00e7in Toz ve \u00c7\u00f6z\u00fcc\u00fc 500 Iu\/10 Ml 1 Flakon) v  Vazopressin geri \u00f6denme ko\u015fullar\u0131 d\u00fczenlendi.   v  Vedolizumab (Entyv\u0131o \u0130nf\u00fczyonluk \u00c7\u00f6zelti Konsantresi \u0130\u00e7in Toz) etkin maddesinin ayaktan tedavide kar\u015f\u0131lanmas\u0131 sa\u011fland\u0131.  02.11.2024_SUT_KAR\u015eILA\u015eTIRMALI TABLO 06.11.2024.pdf","og_url":"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/2024\/11\/06\/sut-degisikligi-hk\/","og_site_name":"\u015eanl\u0131urfa Eczac\u0131 Odas\u0131","article_published_time":"2024-11-06T09:00:00+00:00","article_modified_time":"2026-01-19T08:12:07+00:00","og_image":[{"width":1024,"height":768,"url":"https:\/\/sanliurfaeo.birodam.org.tr\/wp-content\/uploads\/2025\/09\/urfaeo-logo2.png","type":"image\/png"}],"author":"Yeni Admin","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Yeni Admin","Tahmini okuma s\u00fcresi":"5 dakika"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/2024\/11\/06\/sut-degisikligi-hk\/#article","isPartOf":{"@id":"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/2024\/11\/06\/sut-degisikligi-hk\/"},"author":{"name":"Yeni Admin","@id":"https:\/\/sanliurfaeo.birodam.org.tr\/#\/schema\/person\/f482a8288e46359eb9acced6151e1120"},"headline":"SUT DE\u011e\u0130\u015e\u0130KL\u0130\u011e\u0130 HK.","datePublished":"2024-11-06T09:00:00+00:00","dateModified":"2026-01-19T08:12:07+00:00","mainEntityOfPage":{"@id":"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/2024\/11\/06\/sut-degisikligi-hk\/"},"wordCount":994,"commentCount":0,"publisher":{"@id":"https:\/\/sanliurfaeo.birodam.org.tr\/#organization"},"image":{"@id":"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/2024\/11\/06\/sut-degisikligi-hk\/#primaryimage"},"thumbnailUrl":"https:\/\/sanliurfaeo.birodam.org.tr\/wp-content\/uploads\/2025\/09\/urfaeo-logo2.png","articleSection":["ODA"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/2024\/11\/06\/sut-degisikligi-hk\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/2024\/11\/06\/sut-degisikligi-hk\/","url":"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/2024\/11\/06\/sut-degisikligi-hk\/","name":"SUT DE\u011e\u0130\u015e\u0130KL\u0130\u011e\u0130 HK. - \u015eanl\u0131urfa Eczac\u0131 Odas\u0131","isPartOf":{"@id":"https:\/\/sanliurfaeo.birodam.org.tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/2024\/11\/06\/sut-degisikligi-hk\/#primaryimage"},"image":{"@id":"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/2024\/11\/06\/sut-degisikligi-hk\/#primaryimage"},"thumbnailUrl":"https:\/\/sanliurfaeo.birodam.org.tr\/wp-content\/uploads\/2025\/09\/urfaeo-logo2.png","datePublished":"2024-11-06T09:00:00+00:00","dateModified":"2026-01-19T08:12:07+00:00","breadcrumb":{"@id":"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/2024\/11\/06\/sut-degisikligi-hk\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/2024\/11\/06\/sut-degisikligi-hk\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/2024\/11\/06\/sut-degisikligi-hk\/#primaryimage","url":"https:\/\/sanliurfaeo.birodam.org.tr\/wp-content\/uploads\/2025\/09\/urfaeo-logo2.png","contentUrl":"https:\/\/sanliurfaeo.birodam.org.tr\/wp-content\/uploads\/2025\/09\/urfaeo-logo2.png","width":1024,"height":768},{"@type":"BreadcrumbList","@id":"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/2024\/11\/06\/sut-degisikligi-hk\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Anasayfa","item":"https:\/\/sanliurfaeo.birodam.org.tr\/"},{"@type":"ListItem","position":2,"name":"SUT DE\u011e\u0130\u015e\u0130KL\u0130\u011e\u0130 HK."}]},{"@type":"WebSite","@id":"https:\/\/sanliurfaeo.birodam.org.tr\/#website","url":"https:\/\/sanliurfaeo.birodam.org.tr\/","name":"\u015eanl\u0131urfa Eczac\u0131 Odas\u0131","description":"","publisher":{"@id":"https:\/\/sanliurfaeo.birodam.org.tr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/sanliurfaeo.birodam.org.tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Organization","@id":"https:\/\/sanliurfaeo.birodam.org.tr\/#organization","name":"\u015eanl\u0131urfa Eczac\u0131 Odas\u0131","url":"https:\/\/sanliurfaeo.birodam.org.tr\/","logo":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/sanliurfaeo.birodam.org.tr\/#\/schema\/logo\/image\/","url":"https:\/\/sanliurfaeo.birodam.org.tr\/wp-content\/uploads\/2025\/09\/22022021211638-19929-73208.png","contentUrl":"https:\/\/sanliurfaeo.birodam.org.tr\/wp-content\/uploads\/2025\/09\/22022021211638-19929-73208.png","width":635,"height":635,"caption":"\u015eanl\u0131urfa Eczac\u0131 Odas\u0131"},"image":{"@id":"https:\/\/sanliurfaeo.birodam.org.tr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/sanliurfaeo.birodam.org.tr\/#\/schema\/person\/f482a8288e46359eb9acced6151e1120","name":"Yeni Admin","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/b1bcfc5d55af4e7fc9737f956325e8d9203056464179614b915004d0d1be29d3?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/b1bcfc5d55af4e7fc9737f956325e8d9203056464179614b915004d0d1be29d3?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b1bcfc5d55af4e7fc9737f956325e8d9203056464179614b915004d0d1be29d3?s=96&d=mm&r=g","caption":"Yeni Admin"},"url":"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/author\/yeniadmin\/"}]}},"acf":[],"_links":{"self":[{"href":"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/wp-json\/wp\/v2\/posts\/5347","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/wp-json\/wp\/v2\/comments?post=5347"}],"version-history":[{"count":0,"href":"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/wp-json\/wp\/v2\/posts\/5347\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/wp-json\/wp\/v2\/media\/191"}],"wp:attachment":[{"href":"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/wp-json\/wp\/v2\/media?parent=5347"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/wp-json\/wp\/v2\/categories?post=5347"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/wp-json\/wp\/v2\/tags?post=5347"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}